We serve Chemical Name:3-phenyl-4-sulfanylidenephthalazine-1-carboxylic acid CAS:20988-85-6 to global customers since 2007, Pls send inquiry to info@nbinno.com or visit www.nbinno.com our official website should you have any interests. This site is for information only.
Chemical Name:3-phenyl-4-sulfanylidenephthalazine-1-carboxylic acid
CAS.NO:20988-85-6
Synonyms:1-Phthalazinecarboxylic acid, 3,4-dihydro-3-phenyl-4-thioxo-;3-phenyl-4-thioxo-3,4-dihydrophthalazine-1-carboxylic acid;QC-3682;RW3995;3-Phenyl-4-thioxo-3,4-dihydro-1-phthalazinecarboxylic acid
Molecular Formula:C15H10N2O2S
Molecular Weight:282.317
HS Code:
Physical and Chemical Properties:
Melting point:N/A
Boiling point:491.0±28.0 °C at 760 mmHg
Density:1.4±0.1 g/cm3
Index of Refraction:1.699
PSA:87.21000
Exact Mass:282.046295
LogP:2.32
Material Safety Information (Applicable for Hazard Chemicals)
RIDADR:
Packing Group:
Contact us for information like 1-Phthalazinecarboxylic acid, 3,4-dihydro-3-phenyl-4-thioxo- chemical properties,Structure,melting point,boiling point,density,molecular formula,molecular weight,3-Phenyl-4-thioxo-3,4-dihydro-1-phthalazinecarboxylic acid physical properties,toxicity information,customs codes,safety, risk, hazard and MSDS, CAS,cas number,RW3995 Use and application,3-Phenyl-4-thioxo-3,4-dihydro-1-phthalazinecarboxylic acid technical grade,usp/ep/jp grade.
Related News: Steven M. Fruchtman, M.D., President and Chief Executive Officer of Onconova, added ��The rigosertib Pre-approval Access Program is a key strategic initiative for Onconova. 3-phenyl-4-sulfanylidenephthalazine-1-carboxylic acid manufacturer A key publication in a preclinical model demonstrated rigosertib��s ability to block cellular signaling by targeting RAS effector pathways (Divakar, S.K., et al., 2016: ��A Small Molecule RAS-Mimetic Disrupts RAS Association with Effector Proteins to Block Signaling.�� Cell 165, 643). 3-phenyl-4-sulfanylidenephthalazine-1-carboxylic acid supplier Onconova Therapeutics, Inc. and Inceptua Medicines Access (a business unit of the Inceptua Group) recently announced they have entered into a collaboration to make available intravenous rigosertib via a Pre-approval Access Program in selected countries around the world. 3-phenyl-4-sulfanylidenephthalazine-1-carboxylic acid vendor You will find the name and amount of the active ingredient contained in the medicine on the package of OTC (over-the-counter) drugs. 3-phenyl-4-sulfanylidenephthalazine-1-carboxylic acid factory A key publication in a preclinical model demonstrated rigosertib��s ability to block cellular signaling by targeting RAS effector pathways (Divakar, S.K., et al., 2016: ��A Small Molecule RAS-Mimetic Disrupts RAS Association with Effector Proteins to Block Signaling.�� Cell 165, 643).